Fig. 4.

Knockdown of ERK1/2 inhibits the replication of SADS-CoV. (A and B) Vero E6 and IPI-2I cells were untreated (No treat), treated with transfection reagent only (mock), treated with control siRNA (NC), treated with siERK-1 or siERK-2 for 48 h and then infected with SADS-CoV for 36 h. The cells were harvested and analyzed with western blotting with anti-p-ERK1/2, anti-ERK1/2, anti-viral N, or anti-GAPDH antibody. (C) The virus-containing supernatants were collected at 36 hpi and the viral titers calculated with the Spearman–Kärber method. Error bars represent the standard errors of the means of three independent experiments.